Literature DB >> 32771525

Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells.

Yingwei Li1, Haiyang Guo2, Zixiang Wang1, Hualei Bu3, Shourong Wang1, Hao Wang4, Haiyan Fang5, Zhaojian Liu6, Beihua Kong7.   

Abstract

Increased expression of FOXM1 is observed in a variety of human malignancies. The downstream target genes of FOXM1 involved in tumorigenesis and development are not fully elucidated in ovarian cancer. Here, we identified Cyclin F, a substrate recognition subunit of SCF (Skp1-Cul1-F-box protein) complex, and Kinesin Family Member 20A (KIF20A) were transcriptionally regulated by FOXM1 in ovarian cancer. Accordingly, Cyclin F and KIF20A were commonly overexpressed in ovarian cancer. Functionally, forced expression of Cyclin F or KIF20A significantly enhanced while knockdown of them decreased proliferation and invasion of ovarian cancer cells. Importantly, high levels of Cyclin F and KIF20A correlated with poor prognosis in patients with ovarian cancer. Our findings indicate that Cyclin F and KIF20A are functional targets of FOXM1 which might be potential drug targets in ovarian cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyclin F; FOXM1; KIF20A; Ovarian cancer

Mesh:

Substances:

Year:  2020        PMID: 32771525     DOI: 10.1016/j.yexcr.2020.112212

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Small molecule targeting FOXM1 DNA binding domain exhibits anti-tumor activity in ovarian cancer.

Authors:  Zaixin Zhang; Si-Tu Xue; Yan Gao; Yingwei Li; Ziying Zhou; Jing Wang; Zhuorong Li; Zhaojian Liu
Journal:  Cell Death Discov       Date:  2022-06-09

2.  circ_0025033 promotes ovarian cancer development via regulating the hsa_miR-370-3p/SLC1A5 axis.

Authors:  Huiping Ma; Shuyun Qu; Yao Zhai; Xiaofeng Yang
Journal:  Cell Mol Biol Lett       Date:  2022-10-22       Impact factor: 8.702

3.  Integrated Analysis of Transcriptome Data Revealed AURKA and KIF20A as Critical Genes in Medulloblastoma Progression.

Authors:  Bo Liang; Yan Zhou; Jiji Jiao; Lixia Xu; Yan Yan; Qiaoli Wu; Xiaoguang Tong; Hua Yan
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

4.  Identification of potential markers for differentiating epithelial ovarian cancer from ovarian low malignant potential tumors through integrated bioinformatics analysis.

Authors:  Wende Hao; Hongyu Zhao; Zhefeng Li; Jie Li; Jiahao Guo; Qi Chen; Yan Gao; Meng Ren; Xiaoting Zhao; Wentao Yue
Journal:  J Ovarian Res       Date:  2021-03-16       Impact factor: 4.234

5.  Splicing Factor DDX23, Transcriptionally Activated by E2F1, Promotes Ovarian Cancer Progression by Regulating FOXM1.

Authors:  Chen Zhao; Yingwei Li; Chunping Qiu; Jingying Chen; Huan Wu; Qiuman Wang; Xinyue Ma; Kun Song; Beihua Kong
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

6.  Development and Validation of a Combined Glycolysis and Immune Prognostic Model for Melanoma.

Authors:  Yang Yang; Yaling Li; Ruiqun Qi; Lan Zhang
Journal:  Front Immunol       Date:  2021-10-01       Impact factor: 7.561

7.  Long noncoding RNA SH3PXD2A-AS1 promotes NSCLC proliferation and accelerates cell cycle progression by interacting with DHX9.

Authors:  Yeqing Zhou; Hongmei Yong; WenJie Cui; Sufang Chu; Minle Li; Zhongwei Li; Jin Bai; Hao Zhang
Journal:  Cell Death Discov       Date:  2022-04-11

8.  The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.

Authors:  Valeria A Copello; Kerry L Burnstein
Journal:  Oncogene       Date:  2022-04-13       Impact factor: 8.756

Review 9.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

10.  Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.

Authors:  Yalu Zhang; Qiaofei Liu; Ming Cui; Mengyi Wang; Surong Hua; Junyi Gao; Quan Liao
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.